BioNTech (BNTX) PT Lowered to $120 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts BNTX Hot Sheet
Price: $88.17 --0%
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 20 | New: 16
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 20 | New: 16
Join SI Premium – FREE
Goldman Sachs analyst Chris Shibutani lowered the price target on BioNTech (NASDAQ: BNTX) to $120.00 (from $140.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Methanex (MEOH) PT Raised to $63 at JPMorgan Amid Higher Methanol Prices
- JPMorgan (JPM) PT Raised to $400 at UBS
- U.S. Bancorp (USB) PT Raised to $66 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
